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Introduction
Familial Mediterranean fever (FMF) is an autosomal
recessive disease associated with a number of mutations
of the MEFV gene. To date 246 variants responsible for
the disease were identified, one such a variant is E148Q
in exon 2. The role of E148Q variant in the development
of FMF remains inconclusive. Some authors believe it
causes the disease, whereas others favor the concept of a
non causative role.
Objectives
The aim of this study was to perform MEFV gene
sequence analysis in E148Q homozygous patients in order
to detect an associated novel mutation/variant; to deter-
mine the frequency of E148Q allele in healthy society, and
ultimately, to clarify the controversy about whether E148Q
is a disease causing mutation or a benign polymorphism.
Methods
Patients with homozygous E148Q variation previously
determined by strip assay were evaluated. FMF clinical
forms were filled in for those. All coding exons including
exon-intron boundaries of MEFV gene were sequenced
using DNA obtained from peripheral blood lymphocytes.
E148Q allele frequencies of the parents and that of
control group consisting of 100 healthy individuals were
determined.
Results
Eighteen E148Q homozygous patients were studied. Age
at the onset of disease was 5±3.7 (median 5) years. 44% of
the patients were males and 56% were females. Presenting
manifestations were abdominal pain (78.5%), fever (71.4%),
arthralgia (57.1%), pleuritis (28.5%) and myalgia (7.1%).
With colchicine treatment, significant decrement in
annual number of attacks, duration of attacks and disease
activation scores was observed (p<0.05). There was no
difference in terms of achievement of full or partial
remission, possessing low or moderate disease activation
score, living without attack or with >20 attacks/year
between groups carrying associated variants (detected as
R314R, P369S, R408Q, E474E, Q476Q, D510D, P588P)
and those with no associated variants. In control group
consisting of 100 healthy individuals, the frequency of
E148Q allele was found to be 6.5%.
Conclusion
The frequency of E148Q variant in healthy population was
found to be 6.5% in contrast to a previous report as 12%
in Turkey. The E148Q variant may be related with disease
since most of the patients carrying this specific variant
were symptomatic (78% of our patients) and responsive to
colchicine treatment, and no other variants in any coding
region of the gene were detected by direct sequence
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